Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by greaterfoolFredon Jul 24, 2021 11:11am
149 Views
Post# 33600785

RE:RE:RE:RE:A 3rd CR at 450 days?

RE:RE:RE:RE:A 3rd CR at 450 days?
Rumpl3StiltSkin wrote:
greaterfoolFred wrote: At 450 days we see 23-8=15 subjects.  This is the 3 from phase one plus the screwed up 12 from phase two.  If we remove the 1 nr and 2 cr from phase one, that leaves 1 cr, 1 pr, and 10 nr for the screwed up 12.  I say leave them out of the analysis.  If they weren't treated properly then their results should not be counted.  Start the analysis at patient 13. 


I agree, I think TLT will only have to treat ~ 40 patients before we will see the CR % up where it should be, especially if they are allowed to remove the 12 that didn't get this new 'optimized' procedure. Phase 1 patients didn't recieve this procedure, yet 2 were lucky to have CRs at 450 days.



Yes, and it shouldn't take too much longer to treat one or two dozen more patients when all sites are treating.  The regulators would want to see patients treated at all (or at least many) sites before looking at data anyway.  As far as the treatment protocol goes, study 1b was very similar to what they are doing now; no fancy reflectance measurement / monte carlo simulation, just light dosage based on bladder surface area.  And now two treatments instead of just one.
I think that in the long run we will be very happy.  GLTA
<< Previous
Bullboard Posts
Next >>